A new platform for ultra-high dose rate radiobiological research using the BELLA PW laser proton beamline
Jianhui Bin, Lieselotte Obst-Huebl, Jian‐Hua Mao, K. Nakamura, Laura Geulig, Hang Chang, Qing Ji, Li He, Jared De Chant, Zachary Kober, A. J. Gonsalves, S. S. Bulanov, S Celniker, C. B. Schroeder, C. G. R. Geddes, E. Esarey, Blake A. Simmons, T. Schenkel, Eleanor A. Blakely, Sven Steinke, Antoine M. Snijders
Abstract
Abstract Radiotherapy is the current standard of care for more than 50% of all cancer patients. Improvements in radiotherapy (RT) technology have increased tumor targeting and normal tissue sparing. Radiations at ultra-high dose rates required for FLASH-RT effects have sparked interest in potentially providing additional differential therapeutic benefits. We present a new experimental platform that is the first one to deliver petawatt laser-driven proton pulses of 2 MeV energy at 0.2 Hz repetition rate by means of a compact, tunable active plasma lens beamline to biological samples. Cell monolayers grown over a 10 mm diameter field were exposed to clinically relevant proton doses ranging from 7 to 35 Gy at ultra-high instantaneous dose rates of 10 7 Gy/s. Dose-dependent cell survival measurements of human normal and tumor cells exposed to LD protons showed significantly higher cell survival of normal-cells compared to tumor-cells for total doses of 7 Gy and higher, which was not observed to the same extent for X-ray reference irradiations at clinical dose rates. These findings provide preliminary evidence that compact LD proton sources enable a new and promising platform for investigating the physical, chemical and biological mechanisms underlying the FLASH effect.